Napp Pharmaceuticals has been fined £3.21 million by the Office of Fair Trading (OFT) for abusing a dominant market position. The company was found to have supplied sustained release morphine to patients at excessively high prices, while at the same time supplying the drug to hospitals at discount levels. The OFT has ordered Napp to reduce the price of its...